{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "285 received NCIT, while 32 received AIT after US."
      },
      "Objective": {
        "score": 1,
        "evidence": "We aimed to contribute to the ongoing discussion regarding adjuvant treatment strategies following neoadjuvant chemoimmunotherapy (NCIT) and adjuvant immunotherapy (AIT) after upfront surgery (US) in patients with resectable non-small cell lung cancer (NSCLC)."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Event-free survival (EFS) and overall survival (OS) were assessed using the Kaplan\u2013Meier method."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Before and after PSM, the IT and ChIT groups demonstrated better EFS compared with the no-treatment group."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 6,
    "max_score": 25
  },
  "model": "gpt-4o"
}